Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder

Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first…

Read More

When Drug Price Transparency Isn’t Enough

By KRISTINA SMITH & PHIYEN NGUYEN Policymakers and advocates often promote drug price transparency to lower costs and improve equity. While transparency is an important first step toward accountability and informed public budgeting, it does not guarantee affordable prices or fair access to medicines. Transparency Has Some Benefits Drug price transparency helps show how and…

Read More

Impact of financial incentives on the value of the marginal drug

From an interesting review paper in the Journal of Economic Perspectives by Craig Garthwaite: Although research and development investments clearly respond to market opportunities, the exact benefits created by these incremental investments remain unclear. This is largely because the exact marginal products developed in response to these incentives are elusive to identify. Certainly, the amount…

Read More

Allocating CBO’s Estimates of Federal Medicaid Spending Reductions and Enrollment Loss Across the States

The Congressional Budget Office’s (CBO) latest cost estimate shows that the One Big Beautiful Bill would reduce federal Medicaid spending by $723 billion, with an estimated Medicaid enrollment loss of 10.3 million people in 2034. Building on prior KFF analysis, this analysis allocates these estimated federal spending reductions and enrollment losses across the states.

Read More